Table 3. . Objectives and end points.

Safety run-in cohort
Primary objectives   • To evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies   • To determine the RP2D for combination with daratumumab, pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/dexamethasone	Primary end points   • Incidence of DLTs, AEs, and laboratory abnormalities according to NCI CTCAE v5.0

Dose-expansion cohort
Primary objective   • To evaluate the efficacy of magrolimab in combination with other anticancer therapies in patients with relapsed/refractory MM	Primary end points   • ORR, defined as the percentage of patients who achieve complete response, stringent complete response, partial response, or very good partial response (IMWG 2016 criteria)
Secondary objectives   • To evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies   • To investigate the depth of response, DOR, and survival   • To evaluate the PK and immunogenicity of magrolimab combination therapy in relapsed/refractory MM	Secondary end points   • Incidence of AEs and laboratory abnormalities according to NCI CTCAE v5.0   • DOR (measured from the earliest date of complete response, stringent complete response, partial response, or very good partial response to the earliest date of documented disease progression, relapse, or death from any cause), PFS (measured from the date of the first dose of study treatment to the earliest date of documented relapse, disease progression, or death from any cause), and OS (measured from the date of the first dose of study treatment to the date of death from any cause) (IMWG 2016 criteria)   • Magrolimab concentration vs time and measurements of antidrug antibodies against magrolimab
Exploratory objectives   • To evaluate the impact of magrolimab combination therapy on:   • MRD negativity   • Mutation profiles and mutation burden in myeloma cells   • Immune effector cell composition and signaling molecules   • Prophagocytic/antiphagocytic signal expressed by myeloma cells   • Health-related quality of life   • Time-to-response	Exploratory end points   • MRD negativity rate (IMWG 2016 criteria)   • Mutational profile of myeloma cells and the correlation with clinical response   • Changes from baseline in biomarkers of immune cell recruitment and signaling molecules   • Changes from baseline in known phagocytic regulators in myeloma cells   • Change from baseline in FACT-MM questionnaire   • Time-to-response (IMWG 2016 criteria)

AE: Adverse event; DLT: Dose-limiting toxicity; DOR: Duration of response; FACT-MM: Functional Assessment of Cancer Therapy – Multiple Myeloma; IMWG: International Myeloma Working Group; MM: Multiple myeloma; MRD: Minimal residual disease; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; PK: Pharmacokinetics; RP2D: Recommended phase II dose.